Allergan, Inc.

Ads Therapeutics LLC

Exonhit Therapeutics, Sa

Cloudbreak Therapeutics LLC

Celula, Inc.

Rong Yang

Jinsong Ni

John E Donello

Bertrand Leblond

Eric Beausoleil

Thierry Taverne

Thomas C Malone

Sandhya Rao

Anne-Sophie Casagrande

Matthew P Pando

Sougato Boral

Shimiao Wang

Laurent Desire

Cedric Chauvignac

Norbert D Hagen

Eugene Tu

Mark Wang

William Frank Butler

Haichuan Zhang

Mirianas Chachisvilis

Philippe Marchand

Daniel E Raymond

Van Dinh

Robert Dees

Scott Whitcup

Joon Mo Yang

Cédric Chauvignac

Roshantha A Chandraratna

Richard L Beard

Liming Wang

Ling Li

Janet A Takeuchi

Julie Wurster

Xiaoxia Liu

Smita S Bhat

Jayasree Vasudevan

Thong Huy Vu

Clarence Eugene Hull, Iii

Richard Yee

Kwok-Yin Tsang

Laurent Désiré

Mark M Wang

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

Topical ophthalmological compositions

A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.

Anti-angiogenic antibody-drug conjugates

A composition for use in the treatment of ocular hyperemia includes an anti-angiogenic agent and an α adrenergic receptor agonist. A method for treating ocular hyperemia for a patient includes inhibiting a plurality of kinase receptors of the patient with an MKI; and activating α adrenergic receptor of the patient with an agonist of the receptor.

Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same

Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and a semifluorinated alkane, as a liquid vehicle. The topical ophthalmological composition treats an ocular disease.

Topical ophthalmological atropine free base compositions

A composition for use in the treatment of rosacea includes a multi-kinase inhibitor that inhibits both a Vascular Endothelial Growth Factor Receptor and a Fibroblast Growth Factor Receptor. A method for treating rosacea for a patient includes inhibiting a Vascular Endothelial Growth Factor Receptor of the patient; and inhibiting a Fibroblast Growth Factor Receptor of the patient.

Topical composition for treating rosacea and a method for treating rosacea with the same

A method for treating a meibomian gland dysfunction of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of a cyclic polysaccharide. A steroidal-androgen-free composition includes a cyclic polysaccharide as an active pharmaceutical ingredient for treating a meibomian gland dysfunction of an affected eye.

Compositions for treating meibomian gland dysfunction

A method for treating an eye disease of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of beta-cyclodextrin derivative. The eye disease can be meibomian gland dysfunction, blepharitis, or dry eye disease. A steroidal-androgen-free composition includes a beta-cyclodextrin derivative as a sole active pharmaceutical ingredient. The steroidal-androgen-free composition is an ophthalmic composition.

Compositions and methods for treating eye diseases

VEGF antibody-drug conjugates

Compositions and methods for treating meibomian gland dysfunction

Compositions and methods of using nintedanib for improving the success rate of glaucoma filtration surgery are disclosed herein. Nintedanib can be used alone or in combination with an anti-metabolite drug in a topical or implant eye formulation.

Compositions and methods of using nintedanib for improving glaucoma surgery success

The present invention provides topical dermal compositions including microsphere encapsulated isotretinoin. Pharmaceutically acceptable salts, esters, or amides of isotretinoin are also contemplated for use in the practice of the invention. The compositions of the invention are useful for treating a variety of conditions associated with excess sebum production, such as, for example, acne.

Compositions including encapsulated isotretinoin and methods for use thereof

Growing community of inventors

Mission Viejo, CA, United States of America

Rong Yang